WO2013058579A1 - 시링가레시놀을 포함하는 sirt 1 활성화제 - Google Patents
시링가레시놀을 포함하는 sirt 1 활성화제 Download PDFInfo
- Publication number
- WO2013058579A1 WO2013058579A1 PCT/KR2012/008556 KR2012008556W WO2013058579A1 WO 2013058579 A1 WO2013058579 A1 WO 2013058579A1 KR 2012008556 W KR2012008556 W KR 2012008556W WO 2013058579 A1 WO2013058579 A1 WO 2013058579A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sirt
- composition
- activator
- cells
- expression
- Prior art date
Links
- 239000012190 activator Substances 0.000 title claims abstract description 48
- KOWMJRJXZMEZLD-UHFFFAOYSA-N syringaresinol Chemical compound COC1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(OC)C(O)=C(OC)C=3)CO2)=C1 KOWMJRJXZMEZLD-UHFFFAOYSA-N 0.000 title description 3
- LVUPFEOCDSHRBL-UHFFFAOYSA-N syringaresinol Natural products COc1cccc(OC)c1C2OCC3C2COC3c4c(OC)cccc4OC LVUPFEOCDSHRBL-UHFFFAOYSA-N 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 107
- 102000011990 Sirtuin Human genes 0.000 claims abstract description 103
- 108050002485 Sirtuin Proteins 0.000 claims abstract description 103
- 208000030533 eye disease Diseases 0.000 claims abstract description 37
- 208000026278 immune system disease Diseases 0.000 claims abstract description 30
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 230000006872 improvement Effects 0.000 claims abstract description 20
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 238000001784 detoxification Methods 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 230000014509 gene expression Effects 0.000 claims description 73
- 210000004027 cell Anatomy 0.000 claims description 62
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 30
- 230000002207 retinal effect Effects 0.000 claims description 30
- 210000002865 immune cell Anatomy 0.000 claims description 25
- 230000000391 smoking effect Effects 0.000 claims description 22
- 241000208340 Araliaceae Species 0.000 claims description 21
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 21
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 21
- 235000013399 edible fruits Nutrition 0.000 claims description 21
- 235000008434 ginseng Nutrition 0.000 claims description 21
- 230000032683 aging Effects 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 16
- 208000008589 Obesity Diseases 0.000 claims description 15
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 15
- 239000000194 fatty acid Substances 0.000 claims description 15
- 229930195729 fatty acid Natural products 0.000 claims description 15
- 150000004665 fatty acids Chemical class 0.000 claims description 15
- 235000020824 obesity Nutrition 0.000 claims description 15
- 230000003647 oxidation Effects 0.000 claims description 15
- 238000007254 oxidation reaction Methods 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 230000002438 mitochondrial effect Effects 0.000 claims description 13
- 208000004930 Fatty Liver Diseases 0.000 claims description 12
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 12
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 12
- 208000010706 fatty liver disease Diseases 0.000 claims description 12
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 claims description 9
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 9
- 206010020751 Hypersensitivity Diseases 0.000 claims description 9
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 230000007815 allergy Effects 0.000 claims description 9
- 230000004136 fatty acid synthesis Effects 0.000 claims description 9
- 235000004426 flaxseed Nutrition 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 9
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 8
- 201000008937 atopic dermatitis Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 231100000419 toxicity Toxicity 0.000 claims description 8
- 230000001988 toxicity Effects 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 208000026935 allergic disease Diseases 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 6
- 206010007749 Cataract diabetic Diseases 0.000 claims description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 5
- 208000010412 Glaucoma Diseases 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 206010046851 Uveitis Diseases 0.000 claims description 5
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 5
- 201000007025 diabetic cataract Diseases 0.000 claims description 5
- 230000003818 metabolic dysfunction Effects 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 244000000231 Sesamum indicum Species 0.000 claims 1
- 208000026099 carbohydrate metabolic disease Diseases 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 description 45
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 43
- 108090000623 proteins and genes Proteins 0.000 description 35
- 230000001965 increasing effect Effects 0.000 description 26
- 210000001789 adipocyte Anatomy 0.000 description 21
- 238000009472 formulation Methods 0.000 description 21
- 206010061218 Inflammation Diseases 0.000 description 18
- 230000004054 inflammatory process Effects 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 210000003494 hepatocyte Anatomy 0.000 description 15
- 210000000107 myocyte Anatomy 0.000 description 15
- 230000001737 promoting effect Effects 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000002609 medium Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000036039 immunity Effects 0.000 description 9
- 239000003642 reactive oxygen metabolite Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 241000207961 Sesamum Species 0.000 description 8
- 238000009825 accumulation Methods 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 230000006806 disease prevention Effects 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 239000000779 smoke Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000208125 Nicotiana Species 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 description 7
- 101150084750 1 gene Proteins 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108020005196 Mitochondrial DNA Proteins 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000037149 energy metabolism Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000006371 metabolic abnormality Effects 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 229940056692 resinol Drugs 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003440 toxic substance Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 210000003470 mitochondria Anatomy 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 235000020805 dietary restrictions Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000004898 mitochondrial function Effects 0.000 description 4
- 125000000962 organic group Chemical group 0.000 description 4
- -1 phenoxy, thienyl Chemical group 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102100039869 Histone H2B type F-S Human genes 0.000 description 3
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000019504 cigarettes Nutrition 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- VQVUBYASAICPFU-UHFFFAOYSA-N (6'-acetyloxy-2',7'-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(OC(C)=O)C=C1OC1=C2C=C(Cl)C(OC(=O)C)=C1 VQVUBYASAICPFU-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 102000004452 Arginase Human genes 0.000 description 2
- 108700024123 Arginases Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100024853 Carnitine O-palmitoyltransferase 2, mitochondrial Human genes 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000859570 Homo sapiens Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 description 2
- 101000909313 Homo sapiens Carnitine O-palmitoyltransferase 2, mitochondrial Proteins 0.000 description 2
- 101000989606 Homo sapiens Cholinephosphotransferase 1 Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 108091093105 Nuclear DNA Proteins 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 108010041191 Sirtuin 1 Proteins 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 208000018914 glucose metabolism disease Diseases 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000004065 mitochondrial dysfunction Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 210000000608 photoreceptor cell Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 108091008023 transcriptional regulators Proteins 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 1
- MLMQPDHYNJCQAO-UHFFFAOYSA-N 3,3-dimethylbutyric acid Chemical compound CC(C)(C)CC(O)=O MLMQPDHYNJCQAO-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100034033 Alpha-adducin Human genes 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 108010072220 Cyclophilin A Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 101000799076 Homo sapiens Alpha-adducin Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 101100490488 Mus musculus Add3 gene Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 208000031964 Other metabolic disease Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 101000629598 Rattus norvegicus Sterol regulatory element-binding protein 1 Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 244000172730 Rubus fruticosus Species 0.000 description 1
- 235000017848 Rubus fruticosus Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000020827 calorie restriction Nutrition 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- CJYQQUPRURWLOW-YDLUHMIOSA-M dmsc Chemical compound [Na+].OP(=O)=O.OP(=O)=O.OP(=O)=O.[O-]P(=O)=O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O CJYQQUPRURWLOW-YDLUHMIOSA-M 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000001700 effect on tissue Effects 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000011140 membrane chromatography Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000012801 ultraviolet ray absorbent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- SIRT 1 activator comprising siringarecinol
- the present invention relates to a SIRT 1 activator comprising a compound of Formula 1, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention also relates to compositions for the detoxification, metabolic amelioration, eye disease prevention or improvement or immune disease prevention or improvement comprising the SIRT 1 activator.
- Cigarette smoking is now known as an important risk factor for diseases causing major human deaths.
- the main diseases that cause smoking include cerebrovascular diseases such as lung cancer, chronic obstructive pulmonary disease (C0PD), coronary artery disease, and stroke. , Heart attack, circulatory disease, throat cancer, oral cancer.
- Tobacco smoke contains about 4, 000 toxic substances such as carcinogens. Among them, tar and nicotine, which are a combination of various toxic substances, are known as major toxic substances. Toxic components in tobacco inhibit SIRT 1, a human longevity gene, making it vulnerable to serious diseases such as inflammation or chronic obstructive pulmonary disease (C0PD). Smoking is also known to cause mitochondrial dysfunction.
- Obesity generally occurs when energy inflow is greater than body energy consumption. Specifically, surplus energy is stored in the fatty tissue in the form of triglycerides. Adipose tissue can store large amounts of surplus energy like a rubber balloon, but at the same time increases the size of fat cells. In addition, if the amount of surplus energy to be stored cannot be handled only by adipose tissue, lipid dysregulation in which energy is stored in other tissues such as muscle and liver occurs, and lipo oxicity occurs. In addition, the fat stored in each tissue is converted into free fatty acids through lipolysis. The free fatty acids are used to neutralize the insulin signaling system through signaling mechanisms such as JNK and PKC. It is known.
- Inhibition of the insulin signaling system inevitably leads to insulin resistance, which causes various metabolic diseases such as hyperglycemia, hyperlipidemia, hypercholesterolemia, type 2 diabetes, fatty liver, and the like. As such, obesity is more serious because it is accompanied by various adult diseases as well as cosmetic problems.
- the ocular retina is an organ belonging to the central nervous system. Mature retinal cells, like most neurons in the brain, do not divide in normal state. Therefore, when the function of the retinal cells is reduced, the aging progresses easily because abnormalities appear in the functions of tissues and organs as compared to other systems. Oxidative stress is the main cause of retinal cell deterioration. Tissues containing the retina, optic nerve, photoreceptor cells, and lens, which make up the eye, are responsible for oxidative damage such as light and ultraviolet rays. Because it is constantly exposed. Oxidative damage causes damage to the mitochondrial DNA in the eye cells, and since mitochondria lack enzymes that can repair the damaged DNA, the damaged mitochondria accumulate in the cells over time.
- the mitochondrial DNA becomes unstable, it causes modification of the synthesized mitochondrial protein, resulting in a decrease in the mitochondrial membrane potential difference, followed by a decrease in the mitochondrial energy (ATP) generation and relatively increased generation of reactive oxygen species.
- ATP mitochondrial energy
- the most widely known method of delaying aging of the eye is an indirect method of applying antioxidants that can reduce oxidative stress.
- the immune response is energy . ... not an essential banung and metabolism better. Blow for maintaining the homeostasis of the body. Because innate immunity is the primary defense against externally specific infectious agents, the resulting reactions to inflammation are endless. It's a sign that you're defending your body from outside intrusion. These inflammatory reactions are subject to strict control because they have a very large effect on cells and tissues. If the inflammatory response is not properly controlled, hay fever
- the present invention seeks to provide an SIRT 1 activator that activates SIRT 1.
- the present invention seeks to provide a composition having an excellent detoxifying effect.
- the present invention is to provide a composition having an excellent metabolic prevention or improvement effect, specifically by controlling the fat metabolism having an excellent metabolic prevention or improvement effect.
- the present invention provides an excellent effect of preventing or improving eye diseases, specifically, retinal cells
- SIRT KSirtuin 1 To increase the expression and mitochondrial synthesis to provide a composition having the effect of preventing or improving aging eye disease.
- the present invention is to provide a composition having an effect of preventing or ameliorating an immune disease, specifically, by promoting SIRT 1 expression and differentiation from immune cells to type 2 immune cells.
- SIRT 1 activator comprising the compound of Formula 1, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
- the 3 ⁇ 4,, 3 ⁇ 4 or 3 ⁇ 4 are independently a straight-chain (unbranched) or branched (branched) A, to the alkoxy group (alkoxy group) a C 18 alkyl group (alkyl group), to C 18, the ( ⁇ my not alkenyl of C 18 An alkenyl group, to an alkynyl group of C 18 or a cyclic alkyl group of C 3 to C 6 ,
- the 3 ⁇ 4,, 3 ⁇ 4,, 3 ⁇ 4, 11 ⁇ 2 or R u are independently hydrogen or a straight-chain (unbranched) or alkoxy group (alkoxy group) of the basin (branched), to C 18 alkyl group (alkyl group), to C 18 of , To ' C 18 alkenyl group, to C 18 alkynyl group, C 3 to C 6 cyclic alkyl group (cyclic alkyl group).
- One aspect of the invention provides a detoxification composition comprising a SIRT 1 activator.
- One aspect of the present invention provides a composition for preventing or improving metabolic disorders comprising the SIRT 1 activator.
- One aspect of the present invention provides a composition for preventing or ameliorating eye diseases, including an SIRT 1 activator.
- One aspect of the present invention provides a composition for preventing or improving immune disease, including an SIRT 1 activator.
- SIRT 1 activators increase the expression of SIRT KSirtuin 1) and promote the activity of SIRT 1.
- the composition according to the present invention has an excellent detoxifying effect, particularly the toxicity due to smoking, by promoting the activity and cell activity of SIRT 1 reduced due to smoking.
- composition according to the present invention increases the expression of SIRT KSirtuin 1), inhibits fatty acid synthesis and promotes fatty acid oxidation, and increases the expression of PGC 1, metabolic dysfunction, specifically obesity, crab type 2 It is excellent in preventing and improving diabetes, hyperlipidemia or fatty liver.
- composition according to the present invention is also effective in promoting SIRT 1 expression of retinal cells, enhancing mitochondrial biosynthesis, and normalizing mitochondrial function to prevent or improve eye diseases, particularly aging eye diseases. .
- composition according to the present invention promotes SIRT 1 expression of immune cells, inhibits inflammatory reaction, and can convert immune cells into type 2 immune cells to enhance immunity, in particular allergy, atopic dermatitis, hay fever. Or it is excellent in preventing or ameliorating immune diseases such as rheumatoid arthritis.
- 1 is a schematic view showing a method for separating and purifying shiringaresinol from ginseng fruit extract.
- Figure 2 is a graph showing the effect of promoting the SIRT 1 expression of siringaresinol.
- Figure 3 is a graph showing the cell activity promoting effect of shiringaresinol.
- Figure 4 is a graph showing the expression changes of SIRT 1 gene after treatment with 20, 50, 100 ⁇ of siringaresinol to human adipocytes, hepatocytes and myocytes.
- FIG. 5 is a graph showing the expression reduction of genes related to fatty acid synthesis in human adipocytes treated with 50 ⁇ of cyringaresinol.
- FIG. 6 is a graph showing a decrease in expression of genes involved in fatty acid synthesis in human hepatocytes treated with 50 ⁇ of cyringaresinol.
- FIG. 7 is a graph showing a decrease in expression of genes involved in fatty acid synthesis in human myocytes treated with 50 ⁇ of cyringaresinol.
- FIG. 8 illustrates the association of fatty acid oxidation in human adipocytes treated with 50 ⁇ of cyringaresinol.
- FIG. 9 is a graph showing the increased expression of genes involved in fatty acid oxidation in human hepatocytes treated with 50 ⁇ M of cyringaresinol.
- FIG. 10 is a graph showing increased expression of genes involved in fatty acid oxidation in human myocytes treated with 50 ⁇ of cyringaresinol.
- FIG. 11 is a graph showing that fatty acid oxidation is increased in human adipocytes, hepatocytes, and myocytes treated with 50 ⁇ of cyringaresinol.
- FIG. 12 is a graph showing the increased expression of PGC 1 ⁇ , an energy metabolic regulator gene, in human adipocytes, hepatocytes, and myocytes treated with 50 ⁇ of cyringaresinol.
- FIG. 13 is a graph showing the increased expression of PGC 1 ' ⁇ , which is an energy metabolism regulating gene in human adipocytes, hepatocytes and myocytes treated with 50 ⁇ of cyringaresinol.
- FIG. 14 is a graph showing the increased expression level of SIRT 1 gene in aged retinal epithelial cells treated with siringarecinol.
- FIG. 15 is a graph showing mitochondrial biosynthesis levels in aged retinal epithelial cells treated with siringarecinol.
- 16 shows energy ( ⁇ ) in aged retinal epithelial cells treated with siringarecinol.
- 17 is a graph showing increased SIRT 1 gene expression in human peripheral blood mononuclear cells treated with siringarecinol.
- FIG. 18 is a graph showing that generation of reactive oxygen species is inhibited in human peripheral blood mononuclear cells treated with siringarecinol. ⁇
- 19 is a graph showing the decrease in the expression of inflammatory anti-ung genes in human peripheral blood mononuclear cells treated with siringarecinol.
- FIG. 20 is a graph showing that migration of human peripheral blood mononuclear cells treated with siringarecinol and deposition in tissues are inhibited.
- FIG. 21 is a graph showing that expression of genes involved in the conversion of human peripheral blood mononuclear cells treated with siringarecinol to type 2 immune cells is promoted.
- extract is a broad concept including all materials obtained by extracting the components of natural products, regardless of the extraction method, the extraction solvent, the extracted components or the form of the extract.
- substituents for example, each independently hydroxyl, phenoxy, thienyl, furyl, pyridyl, cyclonuclear, alkylal Cole, alkyl di-alcohol or any which may be substituted with a substituted phenyl (10 acyclic hydrocarbon group; a hydroxyl, hydroxymethyl, C 5 which may be substituted with methyl or amino-cyclic 6 hydrocarbons group; or a sugar
- sugar residues refers to a group upon removal of one hydrogen atom from a polysaccharide molecule and, therefore, derived from, for example, a monosaccharide or a ligosaccharide. May mean a moiety.
- pharmaceutically acceptable means that government or equivalent regulatory body approves the use of animals, more specifically humans, by avoiding significant toxic effects when used in conventional medicinal dosages. Means that it can be received or approved, listed on a pharmacopeia, or recognized as another general pharmacopeia.
- “pharmaceutically acceptable salt 1 ” means a salt according to one aspect of the invention that is pharmaceutically acceptable and has the desired pharmacological activity of the parent compound.
- Inorganic acids such as hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, or the like; or acetic acid, propidic acid, nucleoanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, male Acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3- (4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2 'hydroxyethane Sulphonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalen
- SIRT 1 activator comprising a compound of formula ' 1, a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient, [Formula 1]
- The, 3 ⁇ 4 or R 4 are independently a straight-chain (unbranched) or branched (branched) A, to the alkoxy group (alkoxy group) a C 18 alkyl group (alkyl group), to C 18, the ( ⁇ my not alkenyl of C 18 An alkenyl group, an alkynyl group of C 18 to C 18 or a C 3 to C 6 cyclic alkyl group, and 3 ⁇ 4, R 6 , R 7 , R 8 , R 9 , R 10 or R u are independently hydrogen or a straight-chain (unbranched) or branched (branched), the alkyl group to C 18 (alkyl group), to C 18 alkoxy group
- alkoxy group to C 18 alkenyl group (alkenyl group), an alkynyl group of to 18 C
- the compound may be siringaresinol. '
- shiringaresinol (3 1 ⁇ 6 ⁇ 1101)
- flaxseed, yellowish white, orange, sesame and ginseng fruit It can be extracted from one or more of.
- flaxseed, yellowish white, organo and sesame seeds include all parts of the plant, for example, the leaves, stems, roots, fruits or seeds of each plant, and ginseng fruit includes ginseng fruit peel or flesh.
- the "shiringaresinol" is extracted from at least one selected from the group consisting of water, an organic solvent and a mixture of water and an organic solvent of at least one of flaxseed, yellowish white cucumber, sesame and ginseng fruit. It can be obtained by.
- the organic solvent includes, but is not limited to, one or more selected from the group consisting of alcohol, acetone, ether, ethyl acetate, diethyl ether, ethyl methyl ketone and chloroform.
- the alcohol includes a lower alcohol of C ⁇ c 5, the lower alcohol of c ⁇ c 5 is a group consisting of methane, ethane, isopropyl alcohol, n-propyl alcohol, n—butane and isobutane Including but not limited to one or more selected from.
- SIRT 1 activator preferably contains 0.0001 to 10% by weight of the active ingredient based on the total weight of the activator, in the range of SIRT 1 activity promoting effect and no toxicity It may be used above or below the above range depending on the intended use. If included in the above range is not only suitable to exhibit the intended effect of the present invention, but also to satisfy both the stability and safety of the formulation . It may be appropriate to use the above range in terms of cost effectiveness. Specifically, when the compound of Formula 1, specifically, Shirringaleno is less than 0.0001% by weight SIRT 1 can not be activated, when it exceeds 10% by weight it may lower the safety and formulation stability.
- the active ingredient of the present invention is 0.0005 to 8% by weight, 0.001 to 6% by weight, or 0.01 to 4% by weight of a molten stage,
- the siringaresinol may be included in at least one extract selected from flaxseed, yellowish white, organo, sesame and ginseng fruit. All.
- the method for separating and purifying the siringaresinol from ginseng fruit may comprise the following steps. Preparing an alcohol extract of ginseng fruit pulp; Eluting the prepared alcoholic extract with a solvent comprising at least one of alcohol and water to obtain a fraction; And performing chromatography, in particular thin membrane chromatography (TLC), using an organic solvent as the developing solvent for the obtained fraction.
- the organic solvent includes at least one selected from the group consisting of alcohol, acetone, ether, ethyl acetate, diethyl ether, ethyl methyl ketone, and chloroform, and alcohols include alcohols of C1 to C5.
- the composition according to one aspect of the present invention may comprise as an active ingredient of the ring sirengarinolol purified as described above.
- One aspect of the invention provides a detoxification composition comprising the SIRT 1 activator.
- detoxification means to remove the action of toxic substances introduced into the body
- the SIRT 1 activator can detoxify toxic substances introduced into the body,
- SIRT KSirtuin 1 one of deacetylases, physically binds PGC-la at several lysine sites to deacetylate PGC-la, thereby activating PGC-la.
- Activated PGC-la interacts with transcription factors to promote mitochondrial biosynthesis and remove cytotoxic substances such as free radicals.
- the compound of formula 1, including siringaresinol can promote the reduced SIRT 1 activity and cellular activity due to smoking to detoxify the toxicity due to smoking. Therefore, the composition containing the compound of Formula 1 containing the cyringa resinol may have a detoxifying effect.
- siringaresinol may be included in the composition as an extract of flaxseed, yellowish white, scabbard, sesame and ginseng fruit, and may be included as a particularly effective fraction for detoxification.
- the composition for decryption in accordance with one aspect of the present invention is from 0.001 eu amount of JL o of the 0-eu "in the amount of 1, eu in iko yo Ql 0" of i. 3 ⁇ 4 amount eu naeja 10 increased based on the total weight of the composition More specifically, it may include from 0.1% to 5% by weight of the SIRT 1 activator.
- the SIRT 1 activator is less than 0.01% by weight, sufficient detoxification effect may not be obtained, and when it exceeds 20% by weight, safety and formulation stability may be lowered.
- One aspect of the present invention provides a composition for preventing or improving metabolic abnormalities comprising the SIRT 1 activator.
- Controlling fat metabolism can prevent excessive accumulation of fat, which will prevent and improve obesity.
- One way to prevent excessive accumulation of fat is dietary restriction, or calorie restriction. Restricting your diet can not only help you lose weight, but also improve your metabolic disease by improving your blood lipid levels.
- the expression of SIRT KSirtuin 1 and Sirtuin 1) protein is increased.
- induction of the activity of SIRT 1 without dietary restriction is similar to that of dietary restriction.
- SIRT 1 is a NAD + ⁇ -dependent histone protein deacetylase that regulates energy metabolism such as glucose synthesis, fatty acid oxidation, etc. Therefore, the substance that can control the expression of SIRT 1 may regulate fat metabolism, and further prevent or improve metabolic abnormalities such as obesity, type 2 diabetes, hyperlipidemia, and fatty liver.
- Living organisms consume nutrients to maintain life, digest it, absorb it into body composition, and store it as an energy source. In addition, it decomposes and performs various biological activities with energy released at that time. This phenomenon is called "metabolism”.
- the term "metabolism disorder” means a state in which a living organism including a human or an animal cannot perform the metabolic activity smoothly, and includes a glucose metabolism disorder or a lipid metabolism disorder.
- Glucose metabolism abnormalities or lipid metabolism abnormalities include symptoms or diseases caused by glucose or lipid metabolism disorders, in particular symptoms or diseases caused by excessive accumulation of fat due to fatty acid metabolism disorders, including examples of obesity, diabetes mellitus, Hyperlipidemia or fatty liver.
- the compound of Formula 1 specifically Shiring. Garresinol of SIRT 1. It increases the expression, inhibits fatty acid synthesis and promotes the oxidation of fatty acids, thereby reducing the accumulation of fat in the body.
- GI concretely inhibits the expression of fatty acid synthesis-related genes such as ADDl / SREBPlc, ACC, and FAS, promotes the expression of fatty acid oxidation-related genes such as AC0, CPT1, mCAD, and increases fatty acid oxidation. It can be confirmed from the addition.
- the compound of Formula 1, specifically, the siringrecinol may promote energy metabolism, specifically, fat metabolism, thereby increasing fat consumption in the body and preventing accumulation of excess fat.
- Lingaresinol can be identified by increasing the expression of peroxisome proferant-act ivated receptor coactivator (PGC) 1, which regulates the expression of genes involved in energy metabolism. Therefore, the compound of Formula 1, specifically, a composition containing siringarecinol may prevent or improve metabolic abnormalities such as obesity, anti-diabetes, hyperlipidemia, or fatty liver due to a saccharide or lipid metabolism disorder.
- POC peroxisome proferant-act ivated receptor coactivator
- siringaresinol may be included in the composition as an extract of flaxseed, yellowish white, bramble, sesame and ginseng fruit, among which fractions may be particularly effective in improving metabolic dysfunction.
- Composition according to one aspect of the present invention is SIRT 1 activation in 0.001% by weight to 20% by weight, specifically 0.01% by weight to 10% by weight, more specifically 0.1% by weight to 5% by weight based on the total weight of the composition It may include the agent.
- SIRT 1 activator When included in the above range is not only suitable for showing the intended effect of the present invention, it can satisfy both the stability and stability of the composition, it may be appropriate to use in the above range in terms of cost-effectiveness.
- the SIRT 1 activator is less than 0.01% by weight, it is not possible to obtain a layered metabolic improvement effect, and when it exceeds 20% by weight, safety and formulation stability may be lowered.
- One aspect of the present invention provides an eye disease prevention or improvement composition comprising the SIRT 1 activator.
- SIRT 1 expressed in cells in the retina, such as retinal ganglion cells, inner retinal cells, photoreceptor cells, and retinal pigment epithelial cells, is expressed in retinal cells. less ⁇ -bowl-eu in the presence ⁇ eu and also a eu acceleration o the screen-known that i yo showing the cell killing.
- a substance that increases the expression of SIRT 1 promotes the biosynthesis of mitochondria in retinal cells to normalize its function, and also inhibit the instability of mitochondrial DNA. By reducing cellular damage and death, it is possible to prevent and ameliorate eye diseases, particularly aging eye diseases.
- the compound of Formula 1, specifically, the siringarecinol promotes SIRT 1 expression of retinal cells to reduce the SIRT 1 expression level of aged retinal cells to the SIRT 1 expression level of young retinal cells, May promote mitochondrial synthesis and normalize mitochondrial function, leading to increased energy production and reduced free radical species. Therefore, the compound of Formula 1, specifically, a composition containing siringaresinol as an active ingredient may prevent or improve eye diseases by inhibiting or improving aging of retinal cells.
- eye disease refers to a disease that develops with respect to the eye, and includes eye diseases.
- aging eye disease is an eye disease due to deterioration of biofunction due to aging, as well as eyes exhibiting symptoms similar to those of the disease mainly in the elderly due to deterioration in biofunction than the actual age group.
- the concept includes all diseases.
- eye diseases include eye diseases due to mitochondrial dysfunction or oxidative stress of retinal cells.
- the ocular disease includes aging eye disease, including but not limited to macular degeneration, uveitis, glaucoma, diabetic retinopathy or cataracts, which may include senile macular degeneration.
- siringarecinol may be included in the composition as an extract of flaxseed, yellowish white, organo, sesame and ginseng fruit, and may include a fraction which is particularly effective in preventing or ameliorating eye diseases. .
- the composition according to one aspect of the present invention is based on the total weight of the composition 0.001% to 20% by weight, specifically 0.01% to 10% by weight, more specifically 0.1% 3 ⁇ 4> to 5% by weight of SIRT 1 Activators may be included.
- SIRT 1 Activators When included in the above range is not only suitable for showing the intended effect of the present invention, it can satisfy both the stability and stability of the composition, it may be appropriate to use in the above range in terms of cost-effectiveness. Specifically, when the SIRT 1 activator is less than 0.01% by weight, sufficient eye disease improvement effects cannot be obtained, and when it exceeds 20% by weight, safety and formulation stability may be lowered.
- One aspect of the present invention provides a composition for preventing or improving an immune disease comprising the SIRT 1 activator.
- Immune cells largely pro-inflame inflammatory response to inhibit type 1 immune cells and anti-inf la ⁇ atory response, which act as a defense against false pathogens. Helping tissue reorganization can be divided into type 2 immune cells.
- type 1 immune cells largely pro-inflame inflammatory response to inhibit type 1 immune cells and anti-inf la ⁇ atory response, which act as a defense against false pathogens.
- Helping tissue reorganization can be divided into type 2 immune cells.
- chronic inflammatory conditions with increased inflammatory reactions
- the number of type 1 immune cells causing inflammatory reactions is greatly increased, and it is known that chronic inflammatory conditions are alleviated when inducing differentiation into type 2 immune cells.
- modulating immune cell types can prevent and treat immune diseases such as allergies, atopic dermatitis, hay fever or rheumatoid arthritis.
- SIRT KSirtuin 1, Syr-to-1 dependent histone protein deacetylase
- SIRT KSirtuin 1, Syr-to-1 dependent histone protein deacetylase
- the substance promoting the expression of SIRT 1 may be able to suppress the inflammatory reaction and improve the immune disease.
- the compound of Formula 1, specifically, the siringaresinol is a peripheral blood mononuclear cell (PBMC) including immune cells such as B cells, T cells, macrophages, dendritic cells, NK cells, and the like.
- PBMC peripheral blood mononuclear cell
- Peripheral blood mononuclear eel Is promotes the expression of SIRT1, inhibits inflammatory reactions, one of the innate immune reactions, and forms reactive oxygen species, signaling agents and products of inflammatory reactions. Harms it.
- the compound of Formula 1, specifically, cyringaresinol promotes the expression of transcriptional regulators necessary to induce differentiation into crab type 2 immune cells, such as PGC la and PGC 1 ⁇ , IL-10, arginase Since it increases the genes mainly expressed in type 2 immune cells, such as I, the compound of formula (1), specifically, siringarecinol is found to promote the conversion of immune cells to type 2 immune cells Can be. Therefore, the compound of Formula 1, specifically, the composition containing siringaresinol as an active ingredient may enhance immunity, and may further prevent or improve immune diseases, particularly chronic immune diseases.
- an immune disease is a disease caused by a defense mechanism to protect the body from invasion of external pathogens that may harm the body, including antigen-antibody response, vasodilation, It means a disease that shows various immune responses such as fever and inflammatory reaction.
- the immune disorder is allergy, atopic eupi - is ⁇ of the tube T ⁇ eu salt; comprising the yo eu is buyeom 7 eugeon-choyeol eu eu Ryoma: not limited to euah eu
- siringarecinol is flaxseed, yellowish white, organo, sesame and
- the extract of ginseng fruit may be included in the composition, and among these, fractions particularly effective for preventing or improving immune diseases may be included.
- the composition according to one aspect of the present invention is SIRT 1 activation based on the total weight of the composition 0.001% to 20% by weight, specifically 0.01% to 10% by weight, more specifically 0.1% to 5% by weight It may include the agent.
- SIRT 1 activator When included in the above range is not only suitable for showing the intended effect of the present invention, it can satisfy both the stability and stability of the composition, it may be appropriate to use in the above range in terms of cost-effectiveness.
- the SIRT 1 activator is less than 0,01 wt%, sufficient immune disease prevention or improvement may not be obtained, and when it exceeds 20 wt%, safety and formulation stability may be lowered.
- the detoxification, metabolic disorder prevention or improvement, eye disease prevention or improvement or immune disease prevention or improvement, which is an aspect of the present invention may be an oral composition.
- the composition for detoxifying, preventing or improving metabolic disorders, preventing or improving eye diseases, or preventing or improving immune diseases which is an aspect of the present invention, may be a food composition, and includes a favorite food or a health food composition. .
- the composition may prevent or ameliorate metabolic disorders such as obesity, crab antidiabetes, hyperlipidemia or fatty liver.
- the food composition may prevent or ameliorate eye diseases such as macular degeneration, uveitis, glaucoma, diabetic retinopathy, or cataracts.
- the food composition may prevent or ameliorate an immune disease such as allergy, atopic dermatitis, hay fever or rheumatoid arthritis.
- an immune disease such as allergy, atopic dermatitis, hay fever or rheumatoid arthritis.
- the formulation of the food composition is not particularly limited, but may be, for example, formulated as a liquid such as tablets, granules, powdered drinks, caramel gels, bars, and the like.
- the food composition of each formulation may be suitably selected by a person skilled in the art according to the formulation or purpose of use in addition to the active ingredient, and a synergistic effect may occur when simultaneously applied with other raw materials.
- the detoxification, metabolic disorder prevention or improvement, eye disease prevention or improvement or immune disease prevention or improvement of one aspect of the present invention may be a pharmaceutical composition.
- the pharmaceutical composition may exhibit a detoxifying effect, and in particular, may detoxify the body's toxicity due to smoking.
- the pharmaceutical composition may prevent or improve metabolic abnormalities, and in particular, may prevent or improve obesity, diabetes, hyperlipidemia, or fatty liver.
- the pharmaceutical composition can prevent or treat eye disorders, specifically, it can prevent or treat the sulfur anti-degeneration, uveitis, glaucoma, diabetic retinopathy or cataracts.
- the pharmaceutical composition may enhance immunity and prevent or treat immune diseases, and in particular, may prevent or treat allergy, atopic dermatitis, hay fever or rheumatoid arthritis.
- composition according to one aspect of the present invention may be administered orally, parenterally, rectally, topically, transdermally, intravenously, intramuscularly, intraperitoneally, subcutaneously.
- formulations for administration include tablets ( ⁇ ), pills ( ⁇ ) eu soft and hard shell saelje, and ripje ( ⁇ ), powders, fine granules, solutions, emulsions ( ⁇ ) or pellets best May be, but is not limited to this.
- These formulations may contain, in addition to the active ingredient, dilution crabs (e.g. lactose, dextrose, sucrose, manny, sorbbi, cellulose or glycine), glidants (e.g. silica, talc, stearic acid or polyethylene glycol), or binders.
- the tablets can be prepared by conventional mixing, granulating or coating methods.
- Formulations for parenteral administration may be, but are not limited to, injections, drops, lotions, ointments, gels, creams, suspension emulsions, suppositories, patches or sprays.
- the active ingredient of the pharmaceutical composition according to one aspect of the present invention will vary depending on the age, sex, weight, pathology and severity of the subject to be administered, the route of administration or the judgment of the prescriber. Jeokyongryang determined based on these factors is within the level of ordinary skill in the art, one coming liL ⁇ ⁇ ⁇ eu amount eu is eu! S ⁇ aJmg / kg / euil ⁇ eu LQOmg g / euil u, eubo
- Is 5 m g / kg / day to 50 mg / kg / day may be, but is not limited to this.
- the detoxification, metabolic disorders for prevention or improvement, eye diseases may be a cosmetic composition.
- the cosmetic composition may exhibit a detoxifying effect, specifically, as a hop
- the cosmetic composition may prevent or improve metabolic disorders, and in particular, may prevent the improvement of obesity, diabetes, hyperlipidemia or fatty liver.
- the cosmetic composition may enhance immunity and prevent or treat immune diseases, and in particular, may prevent or treat allergy, atopic dermatitis, hay fever or rheumatoid arthritis. '
- Cosmetic compositions according to the invention may be provided in all formulations suitable for topical application.
- it may be provided in the form of an emulsion obtained by dispersing an oil phase in a solution, an aqueous phase, an emulsion obtained by dispersing an aqueous phase in an oil phase, a suspension, a solid, a gel, a powder, a paste, a foam, or an aerosol composition.
- Compositions of such formulations may be prepared according to conventional methods in the art.
- the cosmetic composition according to the present invention may further comprise a moisturizer, an emollient agent, a surfactant, an ultraviolet ray absorbent, a preservative, a fungicide, an antioxidant, a pH adjuster, organic and inorganic pigments, a fragrance, a sensitizer or a restriction agent. It may include.
- the blending amount of the above components can be easily selected by those skilled in the art within the range that does not impair the object and effect of the present invention, the blending amount is 0,01 to 5% by weight, specifically 0.01 to '3 based on the total weight of the composition Weight%.
- the ginseng fruit pulp was isolated from the siringaresinol.
- Gingival fibroblasts were obtained by biopsy from patients with healthy gingiva. Biopsy specimens obtained Dulbecco's Modified Eagle's Medium (DMEM, Gibco Co., USA) is then washed packed in 15 mi test tube three times contained removed * the blood and foreign materials, 10% FBS (fetal bovine serum, Gibco Co. , USA) and 100% tissue culture dish containing DMEM with 1% antibiotic crab (penicillin G 10,000 units / mi, amphotericin B 25 us / mi, Gibco Co., USA). 15 blades were used to cut into 1 ⁇ 2 and 5-6 pieces were evenly distributed in a 60 mm culture dish.
- DMEM Dulbecco's Modified Eagle's Medium
- MTT [3- (4, 5-dimethy 1 thi azol-2-yl) -2, 5-dipheny 1 tetrazolium bromide dissolved in physiological saline; Sigma, USA] solution was added to each well of 300 ⁇ each incubated for 4 hours. After incubation, the medium was removed, the formazan crystals formed by adding 200 ⁇ dimethyl sulfoxide (DMSO; Junsei, Japan) were dissolved, and then transferred onto a 96-well plate, followed by ELISA analyzer (Spectra MAX 250, Molecular Devices Co., USA). Absorbance was measured at 540 ran. Each experiment was repeated three times. The results are shown in FIG.
- siringarecinol recovered the decrease in cellular activity due to smoking to almost the same level as normal. That is, ci3 ⁇ 4garesinol can detoxify the toxicity caused by smoking by activating cells deactivated by smoking.
- adipocyte dedicated medium (0M—AM, ZENBI0), hepatocyte dedicated medium (HM-2, ZENBI0) and myocyte exclusive medium (S MD, SKM-M, ZENBI0), respectively.
- HM-2, ZENBI0 hepatocyte dedicated medium
- S MD myocyte exclusive medium
- the cells treated with each sample were washed twice with cold PBS and then with Trizol reagent.
- siringarecinol can increase the expression of SIRT 1 in human adipocytes, liver cells and muscle cells in a concentration dependent manner. Based on this, it can be seen that cyringaresinol can improve metabolic abnormalities, specifically lipid metabolic abnormalities.
- the siringaresinol inhibited the expression of genes that induce fatty acid synthesis.
- the siringaresinol increased the expression of genes that promote fatty acid oxidation. Based on this, Shiling. It can be seen that Garesinol can inhibit fat accumulation by inhibiting fat synthesis and at the same time increasing fat consumption.
- the siringaresinol is human adipocytes, hepatocytes and myocytes
- ⁇ can increase fatty acid oxidation. Based on this, it can be seen that siringaresinol can suppress the accumulation of fat in the body.
- siringarecinol can increase the expression of PGC 1 ⁇ and PGC 1 ⁇ in human adipocytes, hepatocytes and myocytes. Based on this, it can be seen that shiring garesinol can suppress energy accumulation by promoting energy metabolism.
- Human retinal epithelial cell line A PE-19 was purchased from ATCC (Manassa, VA, USA) and contains 10% bovine serum, 1% penicillin / streptomycin, amphotericin B, DMEKGibco BRL containing antifungal agents, Grand Island, NY, USA) medium was used to culture in a 5% C0 2 incubator until 70% confluent. "Aging of the retina cells induced by the method of subcultures until it grows to the natural aging process. Population doubling level (PDL) was calculated for each generation until cell growth stopped according to the following equation. PDL values increase with aging cells.
- Y is the number of cells counted at the end of each generation.
- X is the first passaged cell number.
- the cells treated with each sample were washed twice with cold PBS, followed by RIPA buffer (Santa).
- siregaresinol increases the expression of reduced SIRT 1 in concentration-dependent retinal cells, especially young retinal epithelial cells when treated with 100 yM of siregaresinol. Increased to SIRT 1 expression level. Based on this, it can be seen that by increasing the SIRT 1 expression of the Shirring Resinol retinal cells, it is possible to prevent or improve eye diseases, particularly aging eye diseases.
- retinal cells were induced to aging in the presence of 50 and 100 ⁇ of cyringaresinol or with DMS0 as a negative control.
- Cells treated with each sample were washed twice with cold PBS, and then genomic DNA (gDNA) was extracted using FastPure DNA kit (Tokyo, Japan).
- genomic DNA gDNA was used to analyze cytokine oxidase subunit II, a marker of mitochondrial DNA, and Cyclophilin A, a marker of nuclear DNA, through real-time PCR reaction. The amount was quantified and the mitochondrial number was determined by calculating the relative amount of mitochondrial DNA relative to nuclear DNA.
- PCR reactions and analysis were performed using the Rotor-Gene 3000 system (Corbet t Research, Sydney, Australia). The results are shown in FIG.
- Mitochondrial biosynthesis was increased by about 40% and 60%, respectively, compared to cells treated with DMS0 alone. Through this, it can be seen that by increasing the concentration-dependent mitochondrial biosynthesis of aged retinal cell retinal cells, it can be seen that the eye disease can be prevented or improved.
- siringaresinol can increase the energy production of retinal cells in a concentration-dependent manner and at the same time reduce the production of reactive oxygen species to prevent or improve eye diseases.
- Human PBMC was purchased from Research Triangle Park, NC, USA.
- the cells were cultured in a 5% ⁇ 2 incubator until they were 80% confluent in PBMC-only medium (Genbio).
- Siringaresinol dissolved in DMS0 was treated for 24 hours at 20, 50 and 100 ⁇ concentrations.
- Negative controls were treated with DMS0 with a media volume of 1/1000.
- Cells treated with each sample were washed with PBS, and then RA was extracted with Trizol reagent (TRIzol agent, Invitrogen).
- CDNA was synthesized using a reverse transcription system (Ferment as, Glen Burnie, MD, USA) from the 5 / g RNA extracted above. Synthesized cDNA was measured using a primer of SIRT 1 and GAPDH.
- qRT-PCR response and analysis were performed using the Rotor-Gene 3000 system; Corbet t Research, Sydney, Australia. The results are shown in FIG.
- siringarecinol is concentration-dependent in human PBMCs.
- SIRT 1 may increase the expression of SIRT 1. Based on this, it can be seen that siringaresinol promotes the expression of SIRT 1 in peripheral blood mononuclear cells to enhance immunity, prevent immune diseases and RT3 ⁇ 4.
- the cells treated with siringaresinol were treated with only LPS.
- the amount of free radicals decreased by up to about 60% compared to the gun. Based on this, it can be seen that siringaresinol can reduce the amount of free radicals to suppress the inflammatory response, thereby improving immunity and preventing and improving immune diseases.
- Inflammation reaction was induced by pretreatment of knol followed by treatment with LPS.10 ng / ml. Cells treated with each sample were washed with PBS, and RNA and cDNA were sequentially extracted and synthesized. IL-lb, IL-6 for synthesized cDNA. Inflammatory reaction of iNOS, C0X2, ⁇ P9, CCR2 . Relevant gene primers were used to measure expression of each gene. The results are shown in FIG. 19.
- the expression of the inflammatory reaction genes was reduced by up to about 90% compared to po.
- siringaresinol can reduce the inflammatory reaction and enhance immunity and prevent or improve immune diseases.
- Inflammatory reactions were induced by treatment with TNF 10 ng / ml after treatment with siringarecinol or after DMS0.
- PBMCs were treated on differentiated 3T3—L1 adipocytes (GenBio) to determine if PBMCs migrate over adipocytes and deposit by fat cell inflammatory signals. After 48 hours, the remaining PBMCs were removed and the trypsin / EDTA solution was removed and the cells were removed with a single incubator. The number was measured and shown in FIG. 20.
- siringarecinol migrates to adipocytes for PBMCs. And up to about 50% inhibition of deposition.
- shiringarereshol can inhibit the migration and deposition by inflammatory signals of peripheral blood mononuclear cells, and thus, Shiring Garesinol can suppress the inflammatory response to enhance immunity and prevent or improve immune diseases. It can be seen.
- siringaresinol can promote differentiation into type 2 immune cells to peripheral blood mononuclear cells, thereby enhancing immunity and preventing or improving immune diseases.
- composition ratio of the vitamin and mineral mixtures described above is a relatively suitable composition suitable for health foods in a preferred embodiment, but the composition ratio may be arbitrarily modified.
- the above ingredients are mixed according to a conventional method for preparing a health beverage, then heated by stirring at 85 ° C. for about 1 hour, and then sterilized by filtering the resulting solution.
- the ointment was prepared by a conventional method according to the composition shown in Table 1 below. ⁇ 254> [Table 1]
- composition according to the invention comprises a SIRT 1 activator, which has an excellent detoxifying effect, in particular an excellent detoxifying toxicity due to smoking.
- composition according to the present invention is excellent in preventing and improving metabolic disorders, specifically obesity, type 2 diabetes, hyperlipidemia or fatty liver by including an SIRT 1 activator.
- composition according to the present invention includes an SIRT 1 activator and is excellent in preventing or ameliorating eye diseases, particularly aging eye diseases.
- composition according to the present invention includes an SIRT 1 activator and is excellent in preventing or ameliorating immune diseases such as allergy, atopic dermatitis, hay fever or rheumatoid arthritis.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Ophthalmology & Optometry (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014536990A JP6126107B2 (ja) | 2011-10-18 | 2012-10-18 | シリンガレシノールを含むsirt−1活性化剤 |
CN201280062749.8A CN104093406B (zh) | 2011-10-18 | 2012-10-18 | 包含丁香脂素的sirt1活化剂 |
US14/352,444 US9913823B2 (en) | 2011-10-18 | 2012-10-18 | SIRT 1 activator including syringaresinol |
US15/160,239 US10022351B2 (en) | 2011-10-18 | 2016-05-20 | SIRT 1 activator including syringaresinol |
US15/160,218 US11096921B2 (en) | 2011-10-18 | 2016-05-20 | SIRT 1 activator including syringaresinol |
US15/160,197 US9999611B2 (en) | 2011-10-18 | 2016-05-20 | SIRT 1 activator including syringaresinol |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0106561 | 2011-10-18 | ||
KR1020110106561A KR101829331B1 (ko) | 2011-10-18 | 2011-10-18 | 시링가레시놀을 포함하는 해독용 조성물 |
KR10-2011-0108904 | 2011-10-24 | ||
KR10-2011-0108914 | 2011-10-24 | ||
KR1020110108904A KR101866924B1 (ko) | 2011-10-24 | 2011-10-24 | 시링가레시놀을 포함하는 대사 이상증 개선용 조성물 |
KR1020110108914A KR101866925B1 (ko) | 2011-10-24 | 2011-10-24 | 시링가레시놀을 포함하는 눈 질환 개선용 조성물 |
KR10-2011-0109961 | 2011-10-26 | ||
KR1020110109961A KR20130045631A (ko) | 2011-10-26 | 2011-10-26 | 시링가레시놀을 포함하는 면역성 질환 개선용 조성물 |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/352,444 A-371-Of-International US9913823B2 (en) | 2011-10-18 | 2012-10-18 | SIRT 1 activator including syringaresinol |
US15/160,197 Division US9999611B2 (en) | 2011-10-18 | 2016-05-20 | SIRT 1 activator including syringaresinol |
US15/160,239 Division US10022351B2 (en) | 2011-10-18 | 2016-05-20 | SIRT 1 activator including syringaresinol |
US15/160,218 Division US11096921B2 (en) | 2011-10-18 | 2016-05-20 | SIRT 1 activator including syringaresinol |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013058579A1 true WO2013058579A1 (ko) | 2013-04-25 |
Family
ID=48141127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/008556 WO2013058579A1 (ko) | 2011-10-18 | 2012-10-18 | 시링가레시놀을 포함하는 sirt 1 활성화제 |
Country Status (5)
Country | Link |
---|---|
US (4) | US9913823B2 (ko) |
JP (4) | JP6126107B2 (ko) |
CN (4) | CN105796546B (ko) |
HK (3) | HK1226303A1 (ko) |
WO (1) | WO2013058579A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015074655A (ja) * | 2013-10-11 | 2015-04-20 | アミ コスメティック カンパニー リミテッド | 高麗人参果実アギタケ発酵液を含有する化粧料組成物 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130046115A (ko) * | 2011-10-27 | 2013-05-07 | (주)아모레퍼시픽 | 시링가레시놀을 포함하는 혈관 노화 억제용 조성물 |
CN105193835B (zh) * | 2015-10-26 | 2018-10-19 | 天津市南开医院 | 鹅掌楸苷及其苷元在制备防治脓毒症所致肺损伤药物中的用途 |
JP6694780B2 (ja) * | 2016-08-23 | 2020-05-20 | 株式会社真誠プランニング | 脂肪細胞分化促進剤およびその製造方法 |
EP3645024B1 (en) * | 2017-06-30 | 2022-09-14 | N.V. Nutricia | Synbiotic composition for preventing fatty liver disease |
CN109925306A (zh) * | 2019-04-23 | 2019-06-25 | 宁夏医科大学 | 丁香脂素在制备抗类风湿性关节炎药物中的用途 |
CN110179784A (zh) * | 2019-06-06 | 2019-08-30 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 一种丁香脂素在制备治疗抑郁症的药物中的应用 |
CN111067888A (zh) * | 2020-01-15 | 2020-04-28 | 桂林医学院附属医院 | 丁香脂素在制备防治肝脏缺血再灌注损伤药物中的应用 |
CN113679709A (zh) * | 2021-08-23 | 2021-11-23 | 南开大学 | 丁香脂素在制备防治糖尿病肾病药物中的应用 |
WO2023123225A1 (zh) * | 2021-12-30 | 2023-07-06 | 南京紫珑生物科技有限公司 | Sirt1-7蛋白在免疫治疗中的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040033983A (ko) * | 2002-10-16 | 2004-04-28 | 학교법인 상지학원 | 항염증 및 항침해수용 활성을 갖는 리리오덴드린을 함유한가시오가피 수피의 추출물 및 이를 함유하는 조성물 |
KR20050022944A (ko) * | 2003-08-27 | 2005-03-09 | 김형환 | 가시오가피 추출물을 함유하는 혈관질환의 예방 또는 치료제 |
JP2007302644A (ja) * | 2006-05-08 | 2007-11-22 | Rooman Kogyo:Kk | Ap−1モチーフを介する遺伝子発現抑制剤 |
KR20110050772A (ko) * | 2009-11-09 | 2011-05-17 | 부산대학교 산학협력단 | 강력한 sirt1 활성조절용으로써 uva에 의한 피부염증 및 피부노화를 억제하는 레스베라트롤 유사체를 함유하는 조성물 |
KR20110063573A (ko) * | 2008-09-29 | 2011-06-10 | 서트리스 파마슈티컬즈, 인코포레이티드 | 시르투인 조절제로서의 크로메논 유사체 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62292785A (ja) | 1986-06-11 | 1987-12-19 | Jujo Paper Co Ltd | シリンガレジノ−ル類の分離・精製法 |
JP2646421B2 (ja) | 1993-10-12 | 1997-08-27 | 日清製油株式会社 | 肥満予防剤 |
JP3818680B2 (ja) * | 1994-05-12 | 2006-09-06 | サントリー株式会社 | アレルギー症状の予防又は改善剤 |
JPH0995452A (ja) | 1995-07-21 | 1997-04-08 | Res Inst For Prod Dev | 脂肪分解促進剤 |
JPH1180001A (ja) | 1997-09-08 | 1999-03-23 | Toshihiko Osawa | 高脂血症予防剤 |
CN1127492C (zh) | 1997-10-24 | 2003-11-12 | 盐野义制药株式会社 | 抗风湿剂 |
JP3763075B2 (ja) | 1998-04-24 | 2006-04-05 | サンスター株式会社 | 歯周病の予防又は治療用の食品組成物、口腔用組成物及び医薬組成物 |
JPH11310530A (ja) | 1998-04-30 | 1999-11-09 | Maruho Co Ltd | 一酸化窒素産生抑制剤 |
JP2000290198A (ja) | 1999-02-05 | 2000-10-17 | Takeda Chem Ind Ltd | 鼻腔抵抗上昇等の抑制剤 |
JP2002029953A (ja) | 2000-07-19 | 2002-01-29 | Sunstar Inc | 歯周病の予防または治療用の食品組成物、口腔用組成物 |
US7786257B2 (en) * | 2000-12-18 | 2010-08-31 | University Of Kansas | Signal-1/signal-2 bifunctional peptide inhibitors |
JP2002241308A (ja) | 2001-02-21 | 2002-08-28 | Ikeda Mohandou:Kk | 皮膚そう痒症治療薬 |
US20030175777A1 (en) * | 2002-02-04 | 2003-09-18 | Bonagura Vincent R. | Eleutherosides as adjuncts for vaccines and immune modulation |
GB0217920D0 (en) * | 2002-04-23 | 2002-09-11 | Aventis Pharm Prod Inc | Interleukin-4 Gene Expression inhibitors |
KR20030087728A (ko) | 2002-05-09 | 2003-11-15 | 주식회사 남양알로에 | 알로에 베라 겔과 프로폴리스를 포함하는 독성물질 해독용조성물 |
KR100815278B1 (ko) | 2006-07-25 | 2008-03-19 | 주식회사 케이티앤지 | 눈의 산화적 손상을 예방할 수 있는 건강기능식품 조성물 |
KR20080019837A (ko) | 2006-08-29 | 2008-03-05 | 경북대학교 산학협력단 | 염증 억제 및 면역조절 활성을 함유하는 사마귀 추출물 및이를 포함하는 조성물 |
JP2008074746A (ja) | 2006-09-20 | 2008-04-03 | Mie Univ | エゾウコギ抽出物を含有する体重増加抑制剤、及びその製造方法 |
KR20080105470A (ko) | 2007-05-31 | 2008-12-04 | (주)아모레퍼시픽 | 인삼 열매 추출물을 함유하는 비만 예방 및 개선용 식품조성물 |
JP5638807B2 (ja) * | 2007-12-28 | 2014-12-10 | サントリーホールディングス株式会社 | リグナン水酸化酵素 |
JP5455413B2 (ja) * | 2008-03-31 | 2014-03-26 | 株式会社 資生堂 | 血管の成熟化・正常化・安定化剤 |
KR101102031B1 (ko) | 2008-04-11 | 2012-01-04 | 주식회사 한국인삼공사 | 면역질환 예방 또는 치료용 조성물 |
CN102813689B (zh) | 2008-06-18 | 2016-08-10 | 株式会社资生堂 | 淋巴管的稳定剂 |
JP2010209051A (ja) | 2009-03-12 | 2010-09-24 | Morishita Jintan Co Ltd | 脂肪吸収抑制剤 |
JP2011020954A (ja) | 2009-07-15 | 2011-02-03 | Food Industry Research & Development Inst | ウコギ属植物(Eleutherococcusspp.)の抽出物、並びにその調製方法及び使用 |
CN101647850B (zh) * | 2009-09-07 | 2013-04-17 | 天津中医药大学 | 杜仲提取物在制备用于治疗雌激素分泌不足相关疾病药物中的用途 |
CA2776950C (en) * | 2009-10-09 | 2023-11-21 | Nestec S.A. | Use of isoflavones in the prevention or treatment of sarcopenia and muscle atrophy |
US20130090377A1 (en) | 2010-03-31 | 2013-04-11 | Amorepacific Corporation | Composition comprising coumestrol or a bean extract containing coumestrol |
CA2808679C (en) * | 2010-08-20 | 2022-06-14 | Federation Des Producteurs Acericoles Du Quebec | Novel phytochemicals from extracts of maple syrups and maple trees and uses thereof |
KR20130046115A (ko) * | 2011-10-27 | 2013-05-07 | (주)아모레퍼시픽 | 시링가레시놀을 포함하는 혈관 노화 억제용 조성물 |
-
2012
- 2012-10-18 CN CN201610134625.6A patent/CN105796546B/zh active Active
- 2012-10-18 CN CN201280062749.8A patent/CN104093406B/zh active Active
- 2012-10-18 CN CN201610133542.5A patent/CN105708833A/zh active Pending
- 2012-10-18 JP JP2014536990A patent/JP6126107B2/ja active Active
- 2012-10-18 CN CN201610134626.0A patent/CN105708834A/zh active Pending
- 2012-10-18 US US14/352,444 patent/US9913823B2/en active Active
- 2012-10-18 WO PCT/KR2012/008556 patent/WO2013058579A1/ko active Application Filing
-
2016
- 2016-05-20 US US15/160,218 patent/US11096921B2/en active Active
- 2016-05-20 US US15/160,239 patent/US10022351B2/en active Active
- 2016-05-20 US US15/160,197 patent/US9999611B2/en active Active
- 2016-10-31 JP JP2016213316A patent/JP6234536B2/ja active Active
- 2016-10-31 JP JP2016213315A patent/JP6310991B2/ja active Active
- 2016-10-31 JP JP2016213317A patent/JP6463320B2/ja active Active
- 2016-12-23 HK HK16114643A patent/HK1226303A1/zh unknown
- 2016-12-23 HK HK16114644A patent/HK1226304A1/zh unknown
- 2016-12-23 HK HK16114645A patent/HK1226305A1/zh unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040033983A (ko) * | 2002-10-16 | 2004-04-28 | 학교법인 상지학원 | 항염증 및 항침해수용 활성을 갖는 리리오덴드린을 함유한가시오가피 수피의 추출물 및 이를 함유하는 조성물 |
KR20050022944A (ko) * | 2003-08-27 | 2005-03-09 | 김형환 | 가시오가피 추출물을 함유하는 혈관질환의 예방 또는 치료제 |
JP2007302644A (ja) * | 2006-05-08 | 2007-11-22 | Rooman Kogyo:Kk | Ap−1モチーフを介する遺伝子発現抑制剤 |
KR20110063573A (ko) * | 2008-09-29 | 2011-06-10 | 서트리스 파마슈티컬즈, 인코포레이티드 | 시르투인 조절제로서의 크로메논 유사체 |
KR20110050772A (ko) * | 2009-11-09 | 2011-05-17 | 부산대학교 산학협력단 | 강력한 sirt1 활성조절용으로써 uva에 의한 피부염증 및 피부노화를 억제하는 레스베라트롤 유사체를 함유하는 조성물 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015074655A (ja) * | 2013-10-11 | 2015-04-20 | アミ コスメティック カンパニー リミテッド | 高麗人参果実アギタケ発酵液を含有する化粧料組成物 |
Also Published As
Publication number | Publication date |
---|---|
US20160263078A1 (en) | 2016-09-15 |
CN105796546A (zh) | 2016-07-27 |
CN105708833A (zh) | 2016-06-29 |
CN104093406A (zh) | 2014-10-08 |
US10022351B2 (en) | 2018-07-17 |
US9913823B2 (en) | 2018-03-13 |
JP6310991B2 (ja) | 2018-04-11 |
JP2014534966A (ja) | 2014-12-25 |
JP2017048221A (ja) | 2017-03-09 |
CN104093406B (zh) | 2018-09-14 |
HK1226305A1 (zh) | 2017-09-29 |
JP2017048220A (ja) | 2017-03-09 |
US20160263079A1 (en) | 2016-09-15 |
US20140371307A1 (en) | 2014-12-18 |
HK1226304A1 (zh) | 2017-09-29 |
US9999611B2 (en) | 2018-06-19 |
CN105796546B (zh) | 2020-03-03 |
JP6463320B2 (ja) | 2019-01-30 |
US11096921B2 (en) | 2021-08-24 |
US20160263077A1 (en) | 2016-09-15 |
JP6234536B2 (ja) | 2017-11-22 |
JP2017061490A (ja) | 2017-03-30 |
CN105708834A (zh) | 2016-06-29 |
HK1226303A1 (zh) | 2017-09-29 |
JP6126107B2 (ja) | 2017-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6463320B2 (ja) | シリンガレシノールを含むsirt−1活性化剤 | |
JP2019534273A (ja) | モノアセチルジアシルグリセロール化合物を含有する肝炎の予防または治療用組成物 | |
TW201609123A (zh) | 五層龍屬組成物、藉由其投藥之治療方法及其製備方法 | |
WO2011010678A1 (ja) | ポリフェノールを配合してなる経口投与用又は外用組成物、並びにその用途 | |
JP4520089B2 (ja) | ルブロフサリン配糖体含有組成物 | |
JP2015501318A (ja) | シリンガレシノールを含む血管老化抑制用組成物 | |
TW202304422A (zh) | 用於調節皮質醇之體內恆定及改善睡眠品質之組合物以及其使用及製造方法 | |
US20150290105A1 (en) | Composition comprising syringaresinol for improving the skin | |
KR101866925B1 (ko) | 시링가레시놀을 포함하는 눈 질환 개선용 조성물 | |
TW201912177A (zh) | 具美白與抗老功能的臺灣藜殼萃取區分物及其萃取與分離方法 | |
KR100597612B1 (ko) | 항노화 활성이 우수한 현삼 추출물을 포함하는 식품 조성물 | |
KR100535266B1 (ko) | 항노화 활성이 우수한 현삼 추출물 및 이를 포함하는 조성물 | |
JP2018039752A (ja) | Nrf2活性化剤 | |
KR102050063B1 (ko) | 꽃송이버섯 추출물을 포함하는 이상지질혈증 관련 질환 예방 또는 치료용 조성물 | |
KR102567179B1 (ko) | 지페노사이드 화합물을 유효성분으로 포함하는 운동수행능력 향상용 조성물 | |
KR102490378B1 (ko) | 돌외잎 추출물을 유효성분으로 포함하는 운동수행능력 향상용 조성물 | |
KR20150068865A (ko) | 진세노사이드 Rg3를 유효성분으로 포함하는 노화세포 회춘용 조성물 | |
KR101829331B1 (ko) | 시링가레시놀을 포함하는 해독용 조성물 | |
KR102559627B1 (ko) | 유산균발효호박손추출물을 이용한 골질환 예방 및 뼈 기능 개선 조성물 및 그 제조방법 | |
KR102226439B1 (ko) | 코르너스 오블롱가 추출물을 이용한 항염증용 조성물 | |
TW202021604A (zh) | 小火菇屬萃取物與其化合物用於提升atgl基因、lipe基因、ucp1基因、及/或ucp2基因表現量、及/或抑制脂肪累積的用途 | |
KR20130048357A (ko) | 패장 추출물을 유효성분으로 포함하는 염증성 질환의 예방 및 치료용 조성물 | |
KR20210009793A (ko) | 곱슬사초 추출물을 이용한 항염증용 조성물 | |
JP2009143905A (ja) | 治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12840908 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014536990 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14352444 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 07/08/2014) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12840908 Country of ref document: EP Kind code of ref document: A1 |